22 states. $1.25 billion in settlements. Zero federal indictments.
Centene Corporation: A Billion-Dollar Fraud
Centene Corporation, once hailed as a leader in Medicaid management, has found itself embroiled in a massive scandal that reveals how corporate greed can hijack public healthcare.
Over the course of several years, Centene systematically inflated Medicaid drug prices through a practice known as spread pricing, resulting in $1.25 billion in settlements across 22 states. Yet, despite these massive payouts, no federal indictments have been issued, raising questions about how deep the corruption runs and why those responsible haven’t been held accountable.
The Shell Game: How Centene Manipulated the System
At the heart of Centene’s fraudulent activities was its pharmacy benefit manager (PBM) subsidiary, Envolve Health. Envolve wasn’t just a third-party contractor; it was both owned by Centene and contracted by the company to handle Medicaid pharmacy services.
On paper, Envolve was supposed to “negotiate” drug prices with pharmacies. In practice, it acted as a pass-through entity, artificially inflating prices to Medicaid while paying pharmacies far less and pocketing the difference.
Between 2017 and 2022, 22 states, including Ohio, Illinois, New Mexico, and Mississippi, forced Centene to pay back over $1.25 billion after discovering these inflated drug prices.
In Ohio, Envolve was concealed under the deceptive name “Health Net Pharmacy Solutions.” Despite billing Medicaid millions for services rendered, auditors in Kansas found no record of payments.
One leaked 2022 Ohio Attorney General document revealed Centene executives acknowledging their pricing model was “non-compliant with state regs.” Yet, they pushed forward anyway because the profits were simply too significant to forfeit.
Whistleblowers Were Silenced: Centene’s Corporate Culture of Intimidation
Multiple whistleblowers came forward between 2019 and 2023, exposing Centene’s corrupt practices. These whistleblowers, including former Centene employees, state auditors, and pharmacists, have shed light on just how deep the fraud ran.
A former compliance officer in Georgia revealed that executives pressured her to overlook pricing model discrepancies, leading to her resignation.
In Ohio, a rural pharmacist recalled how Medicaid reimbursement rates declined by 30% overnight, with no explanation. She testified she was warned not to ask questions, citing the corporate silence that shrouded the operation: “It was a black box,” she said.
“They wanted it that way.”
Despite their brave efforts, financial settlements designed to bury the truth silenced many of these whistleblowers and forced them into non-disclosure agreements.
Lobbying, Lawsuits, and a Convenient Lack of Federal Scrutiny
Centene’s influence extended far beyond the Medicaid system itself.
Between 2020 and 2024, the company ramped up political contributions by 62%, focusing specifically on healthcare committees and key figures involved in Medicaid policy.
Records indicate Centene fought hard against transparency reforms aimed at PBM reforms that would have revealed their questionable tactics.
Even after reimbursing millions to states, the Department of Justice has not brought criminal charges against any Centene executives, indicating that a mix of lobbying, settlements, and policy influence has effectively protected the company from serious federal examination.
The Bigger Picture: Medicaid Privatization Crisis
Centene’s actions aren’t just an isolated case; they’re indicative of a much larger problem. Today, 72% of Medicaid recipients are served by private Managed Care Organizations (MCOs) like Centene. Many of these MCOs also operate their own PBMs, creating an inherent conflict of interest that regulators have failed to address.
States were promised that privatizing Medicaid would lead to greater efficiency. : In reality, corporate opacity creates enormous opportunities for exploitation in this system. States like New Mexico have admitted that they don’t have the necessary tools to track PBM practices, allowing companies like Centene to thrive in a climate of secrecy.
The Human Cost: Patients Left Behind
The story isn’t just about numbers or settlements; it’s about real people suffering because of Centene’s actions.
In New Mexico (2022), a 7-year-old boy with asthma went two months without medication, resulting in two emergency room visits.
In Mississippi (2021), an elderly woman was charged out-of-pocket for diabetes medication that her plan had claimed was covered.
In Arkansas (2020), a behavioral health clinic filed for bankruptcy after Centene failed to pay its claims for six months, leaving hundreds of vulnerable patients without care.
These cases aren’t anomalies. They’re the predictable result of a system that prioritizes profits over the needs of the sick and vulnerable.
Time to Name It: Healthcare Looting
What Centene has done is not only a scandal; it’s healthcare plundering.
It’s a deliberate, systematic attempt to pull profits out of a public system designed to help those who are most in need. For decades, the company has operated behind subsidiaries and shell companies, essentially avoiding accountability.
Despite reaching a $1.25 billion settlement with the states, Centene executives continue to act recklessly.
The settlements may have ended some cases, but little has been done to stop the corruption that caused it.
Reclaiming Medicaid’s Mission
Policymakers, healthcare advocates, and every single taxpayer should take heed from the Centene scandal.
If the system that’s supposed to protect our most vulnerable citizens can be exploited like this, what’s sacred?
It’s time to demand:
The federal government should impose a ban on PBM spread pricing.
There are safeguards for whistleblowers that are enforced in real-time.
Real-time claims transparency for states.
The public health audit bureau possesses the authority to pursue legal action.
If we don’t, we risk allowing these kinds of corporate abuses to become standard practice.
Conclusion
We cannot simply stand by and let profit seize control of healthcare. The Centene story isn’t a story about fraud; it’s a warning of what occurs when we permit corporate greed to operate uncontrolled in a public system. While patients languish and states struggle to recover their stolen money, one question remains: How many more Centenes are out there, poised to do the very same thing?
